ArticleJournal of clinical pathology1999
Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation.
Article in Journal of clinical pathology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 87 citations in OpenAlex.
- Trial
- Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1.Journal of diabetes research · 2013Trial
- Mechanisms of Podocyte Injury in Kidney Allografts.Kidney360 · 2026Review
- Suramin Affects the Renal VEGF-A/VEGFR Axis in Short-Term Streptozotocin-Induced Diabetes.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Comparison of the surgical resection and infarct 5/6 nephrectomy rat models of chronic kidney disease.American journal of physiology. Renal physiology · 2022Review
- An overview of the efficacy and signaling pathways activated by stem cell-derived extracellular vesicles in diabetic kidney disease.Frontiers in endocrinology · 2022Review
- Article
- Urinary Markers of Podocyte Dysfunction in Chronic Glomerulonephritis.Advances in experimental medicine and biology · 2021Article
- Molecular Mechanisms of Proteinuria in Minimal Change Disease.Frontiers in medicine · 2021Review
- Urinary Markers of Podocyte Dysfunction in Chronic Glomerulonephritis.Advances in experimental medicine and biology · 2021Article
- Mesenchymal Stromal Cells Induce Podocyte Protection in the Puromycin Injury Model.Scientific reports · 2019Article
- Article
- Amniotic fluid stem cell-derived vesicles protect from VEGF-induced endothelial damage.Scientific reports · 2017Article
- The podocyte as a direct target for treatment of glomerular disease?American journal of physiology. Renal physiology · 2016Review
- Effects of extremely low frequency pulsed magnetic fields on diabetic nephropathy in streptozotocin-treated rats.Biomedical engineering online · 2016Article
- GIV/girdin links vascular endothelial growth factor signaling to Akt survival signaling in podocytes independent of nephrin.Journal of the American Society of Nephrology : JASN · 2015Article
- Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes.American journal of physiology. Renal physiology · 2013Article
- Understanding the mechanisms of proteinuria: therapeutic implications.International journal of nephrology · 2012Article
- Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease.Cell and tissue research · 2012Review
- Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.Diabetologia · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate vascular endothelial growth factor (VEGF) mRNA expression in glomerular disease in the context of heavy proteinuria.
methodsNon-radioisotopic in situ hybridisation was performed using a cocktail of 12 deoxyoligonucleotides complementary to VEGF mRNA labelled during solid phase synthesis with 2,4-dinitrophenyl. Archival renal biopsies were studied from cases of minimal change nephropathy, membranous nephropathy, diabetic nephropathy, and controls, matched for age, sex, race, and storage time. Hybrid detection used NBT/BCIP colorimetric development.
resultsMore VEGF mRNA positive glomerular cells per unit cross sectional diameter were seen in minimal change nephropathy (mean (SEM), 19.35 (1.5)) compared with controls (12.6 (1.73)), p < 0.01. In contrast, fewer were seen in diabetic nephropathy (5.93 (0.97)) compared with controls (9.97 (1.25)), p < 0.03. Analysis of membranous nephropathy (10 (1.62)) showed no difference from controls (10.98 (1.51)), NS. In addition, in minimal change nephropathy there was a significant correlation between 24 hour protein excretion at the time of biopsy and the number of VEGF mRNA cells per glomerulus (r = 0.08, p = 0.01).
conclusionsUsing non-radioisotopic in situ hybridisation, VEGF mRNA is almost exclusively expressed by visceral glomerular epithelial cells. Abnormal numbers of cells are seen in both minimal change and diabetic nephropathy. As VEGF exists in a number of functionally distinct isoforms, further study of qualitative VEGF isoform expression in diagnostic groups is indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.